XML 31 R21.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Significant Accounting Policies - Additional Information (Detail)
 3 Months Ended 9 Months Ended
Dec. 18, 2020
shares
Sep. 30, 2022
USD ($)
$ / shares
shares
Sep. 30, 2021
USD ($)
shares
Sep. 30, 2022
USD ($)
Segment
$ / shares
shares
Sep. 30, 2021
USD ($)
shares
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Mar. 31, 2020
shares
Summary Of Significant Accounting Policies [Line Items]                
Net loss | $   $ (10,471,000) $ (9,817,000) $ (29,582,000) $ (25,700,000)      
Cash and cash equivalents | $   65,889,000 $ 94,041,000 65,889,000 $ 94,041,000 $ 84,833,000 $ 114,195,000  
Working capital | $   61,300,000   61,300,000        
Accumulated deficit | $   (144,481,000)   $ (144,481,000)   (114,899,000)    
Cash, cash equivalents and restricted cash, maturity period       three months or less        
Cash equivalents | $   $ 9,200,000   $ 9,200,000   $ 9,200,000    
Number of operating business segments | Segment       1        
Basic weighted average shares outstanding   14,265,905 14,815,852 14,289,729 14,820,822      
Warrants exercise price | $ / shares   $ 0.001   $ 0.001        
Antidilutive securities excluded from computation of earnings per share, amount       8,223,206 674,295      
2014 Stock Incentive Plan [Member]                
Summary Of Significant Accounting Policies [Line Items]                
Increase in number of shares of common stock authorized for issuance               28,816
Common stock, number of shares initially reserved for issuance   0   0        
2014 Employee Stock Purchase Plan [Member]                
Summary Of Significant Accounting Policies [Line Items]                
Increase in number of shares of common stock authorized for issuance               7,204
Common stock, number of shares initially reserved for issuance   24,077   24,077        
2020 Plan [Member]                
Summary Of Significant Accounting Policies [Line Items]                
Common stock, number of shares initially reserved for issuance 4,860,000 3,167,608   3,167,608        
Percentage of issued and outstanding shares of common stock 15.00%              
Equity compensation period 3 years              
Stock Options [Member] | Board of Directors [Member]                
Summary Of Significant Accounting Policies [Line Items]                
Expected life assumption using simplified method, description       For stock options granted to the members of the Company’s board of directors (the “Board”), the Company determined the expected life assumption using the simplified method as the starting point with an average period of twelve (12) months added to take into account for the extended range of time of 12 to 18 months vested stock options granted to Board members may be exercised upon termination.        
Expected life assumption using simplified method       12 months        
Stock Options [Member] | Minimum [Member] | Board of Directors [Member]                
Summary Of Significant Accounting Policies [Line Items]                
Vesting period of stock options granted       12 months        
Stock Options [Member] | Maximum [Member] | Board of Directors [Member]                
Summary Of Significant Accounting Policies [Line Items]                
Vesting period of stock options granted       18 months        
Warrants [Member]                
Summary Of Significant Accounting Policies [Line Items]                
Basic weighted average shares outstanding       509,117        
Anelixis Therapeutics, LLC and Otic Pharma, Ltd.                
Summary Of Significant Accounting Policies [Line Items]                
Ownership interest percentage       100.00%        
Otic Pharma, Inc. [Member]                
Summary Of Significant Accounting Policies [Line Items]                
Ownership interest percentage       100.00%